Myovant Sciences (MYOV US)

Myovant Sciences Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant Sciences develops relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis-associated pain.